C-Rad AB Class B (DE:24C)
FRANKFURT:24C
24C Stock Chart & Stats
€2.83
€0.01(0.40%)
At close: 4:00 PM EST
€2.83
€0.01(0.40%)
Day’s Range― - ―
52-Week Range€2.20 - €3.31
Previous CloseN/A
Volume0.00
Average Volume (3M)162.00
Market Cap
€80.88M
Enterprise Value€698.74M
Total Cash (Recent Filing)€171.20M
Total Debt (Recent Filing)€18.80M
Price to Earnings (P/E)103.1
Beta0.29
Next Earnings
May 06, 2026EPS Estimate
0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.02
Shares Outstanding32,904,050
10 Day Avg. Volume200
30 Day Avg. Volume162
Financial Highlights & Ratios
PEG Ratio-1.27
Price to Book (P/B)3.12
Price to Sales (P/S)2.45
P/FCF Ratio15.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.24
Revenue Forecast (FY)€47.93M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetC‑Rad's very low debt (debt/equity roughly 0.6%–5.4% historically) and rising equity provide durable financial flexibility. This conservative capital structure supports investment in installed base, R&D and service capacity, and cushions the business through demand cycles without forcing dilutive financing.
Structurally High Gross MarginsSustained gross margins near 65%–69% indicate strong product pricing and favorable product mix for SGRT systems and software. High gross profitability supports long-term margin sustainability, funds service and software development, and underpins attractive economics as recurring revenues scale.
Improved Cash Generation In 2025Operating and free cash flow of ~71m in 2025 shows the company's ability to convert earnings into cash when operations perform. Strong cash generation enables reinvestment in installations, service networks and software, and provides a buffer to fund working capital through cyclical equipment sales.
Bears Say
Sharp 2025 Profitability ResetA material drop in net margin to ~2.4% and lower EBIT margin in 2025 signals weakened operational leverage or higher operating costs. If persistent, this compresses the conversion of high gross margins into net profits, limiting internally funded growth and increasing reliance on operational fixes or structural shifts to restore profitability.
Declining Top-line TrendRevenue contraction in 2025 and negative multi‑year growth indicate demand headwinds or slower adoption. A shrinking or stagnating equipment revenue base reduces the flow of new recurring software and service revenues over time, challenging long‑run expansion of higher-margin annuity streams and installed-base monetization.
Cash Flow VolatilityHistorical swings in free cash flow, including negative FCF episodes and an FCF decline in 2025, reduce predictability for reinvestment and dividend or buyback capacity. Volatile cash conversion raises execution risk for service rollouts and R&D spending when margins and revenue are under pressure.
C-Rad AB Class B News
24C FAQ
What was C-Rad AB Class B’s price range in the past 12 months?
C-Rad AB Class B lowest stock price was €2.20 and its highest was €3.31 in the past 12 months.
What is C-Rad AB Class B’s market cap?
C-Rad AB Class B’s market cap is €80.88M.
When is C-Rad AB Class B’s upcoming earnings report date?
C-Rad AB Class B’s upcoming earnings report date is May 06, 2026 which is in 41 days.
How were C-Rad AB Class B’s earnings last quarter?
C-Rad AB Class B released its earnings results on Feb 12, 2026. The company reported €0.018 earnings per share for the quarter, missing the consensus estimate of €0.062 by -€0.043.
Is C-Rad AB Class B overvalued?
According to Wall Street analysts C-Rad AB Class B’s price is currently Overvalued.
Does C-Rad AB Class B pay dividends?
C-Rad AB Class B does not currently pay dividends.
What is C-Rad AB Class B’s EPS estimate?
C-Rad AB Class B’s EPS estimate is 0.04.
How many shares outstanding does C-Rad AB Class B have?
C-Rad AB Class B has 32,904,050 shares outstanding.
What happened to C-Rad AB Class B’s price movement after its last earnings report?
C-Rad AB Class B reported an EPS of €0.018 in its last earnings report, missing expectations of €0.062. Following the earnings report the stock price went down -1.718%.
Which hedge fund is a major shareholder of C-Rad AB Class B?
Currently, no hedge funds are holding shares in DE:24C
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
C-Rad AB Class B
C-Rad AB (publ), together with its subsidiaries, develops, manufactures, and sells systems with applications in radiation therapy for the treatment of cancer worldwide. The company operates through two segments, Positioning and Imaging. Its products include Sentinel 4D CT, a laser-based optical surface scanning system; Catalyst, a 4D surface image guided radiation therapy (SIGRT) solution; Catalyst HD, an SIGRT solution on stereotactic radiation therapy for online patient tracking before and during treatment delivery; Catalyst+, an SIGRT solution for high precision patient positioning, intra-fraction motion management, and respiratory gating; and Catalyst+ HD, a solution for high precision patient positioning, intra-fraction motion management, and respiratory gating for conventional and stereotactic treatment delivery. The company's products also comprise Catalyst Tomo, an enhanced positioning solution for tomotherapy; Catalyst PT, a real-time tracking solution for particle therapy; Cyrpa laser positioning products; cAccessory, which automates the registration and validation of treatment accessories; and cPatient that automates patient identity validation without the need for contact between patients and devices. In addition, it offers installation, application training, and aftersales services. C-Rad AB (publ) was founded in 2004 and is headquartered in Uppsala, Sweden.
Technical Analysis
Paxman AB
―
Senzime AB
―
Bactiguard Holding AB
―
Integrum AB Class B
―
Sedana Medical AB
―